Optimization of the Ocular Surface Prior to Cataract Surgery Using PROKERA

Last updated: March 6, 2025
Sponsor: Jeff Wongskhaluang
Overall Status: Completed

Phase

N/A

Condition

Eye Disease

Vision Loss

Dry Eyes

Treatment

PROKERA

Clinical Study ID

NCT05148507
9132
  • Ages 18-100
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of the study is to assess whether PROKERA can sufficiently stabilize the ocular surface prior to cataract surgery and improve post operative outcomes patients with moderate to severe dry disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. ≥ 18 years of age and plan to undergo cataract surgery

  2. Prior use of DED/keratitis conservative treatments (artificial tears, ointment,Xiidra®, Restasis, warm compresses, etc.) within 30 days

  3. Moderate to severe DED/keratitis (SPEED score ≥ 10)

  4. Total cornea fluorescein staining score ≥ 4 (NEI scale)

  5. Topographic changes such as irregularity, dropout, and higher order aberrations (HOAs; RMS > 0.4) as determined by the investigator

  6. Distorted keratometry mires or inconsistent biometry between 2 consecutive readings (30s apart) as determined by the investigator

Exclusion

Exclusion Criteria:

  1. Use of soft contacts lens, bandage contact lens, or scleral lens within 7 days

  2. Ocular surgery within 3 months

  3. History of refractive surgery (LASIK, keratectomy, radial keratotomy, etc.)

  4. History of clinically significant ocular trauma

  5. Significant posterior corneal astigmatism (≥ 0.75 D)

  6. History of herpetic keratitis

  7. Ongoing ocular or systemic infection

  8. Visually significant retinal pathology

  9. Clinically significant findings observed at screening, including lid abnormalities,epithelial basement membrane dystrophy, Salzmann's nodular degeneration, subclinicalor clinical keratoconus (defined as KISA% index > 6019), ectasia (Belin/Ambrosioenhanced ectasia display final 'D' index > 2.6920), Fuchs' endothelial cornealdystrophy (Using the Classification by Sun et al21), etc.

  10. Short eyes (axial length < 22 mm22, 23)

  11. High myopia (axial length ≥ 26 mm)22, 24

  12. Eyes with glaucoma drainage devices or filtering bleb

  13. Patients with a history of drug reactions to Ciprofloxacin, Amphotericin B,Glycerol, and/or DMEM.

  14. Patient cannot close the eyelid, has an incomplete blink, or demonstrates any othersigns of exposure that cannot be addressed by the investigator

  15. Pregnancy or subject expecting to be pregnant

  16. Use of additional eye medications (i.e. glaucoma eye drops, anti-histamines, etc)

Study Design

Total Participants: 43
Treatment Group(s): 1
Primary Treatment: PROKERA
Phase:
Study Start date:
November 04, 2021
Estimated Completion Date:
January 21, 2025

Study Description

Amniotic membrane has been used to treat many ocular diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States Food and Drug Administration (FDA) in 2003.

Cataract surgery is the most common eye surgery done in the United States. Prior to cataract surgery, machines scan the eyes to calculate which implant is needed at the time of cataract surgery. When a patient has dry eyes, the machines may have inaccurate measurements.

The purpose of the study is to assess whether PROKERA can sufficiently stabilize the ocular surface prior to cataract surgery and improve post operative outcomes patients with moderate to severe dry disease. There will be a maximum of 64 eyes of individuals age 18 and older in the study enrolled at one study site. Each subject will have both eyes evaluated for the study.

Prior to cataract surgery, patients enrolled in the study will have PROKERA device inserted on the surface of the eye. The subject will then come back after about five days to remove the PROKERA device and follow up again in one week and two weeks after the removal of the PROKERA device. During both of the follow up visits, the study doctor will grade symptoms based on a questionnaire, examine eyes, take pictures, and grade the severity of the dry eye disease to determine any changes from the baseline testing.

At the two week visit, cataract surgery will be scheduled, which will be within one to two weeks time. After surgery, a one month postoperative visit will occur, where the same examination procedures are performed as the previous follow up visits.

Connect with a study center

  • Grin Eye Care

    Olathe, Kansas 66061
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.